SCHEMBL18150511

SCHEMBL18150511

Cc1ccc(Cl)c(CBr)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.41
ALDH1A1 P00352 3/20 0.41
S1PR4 O95977 4/20 0.39
HPGD P15428 2/20 0.37
HSD17B10 Q99714 2/20 0.37
USP2 O75604 1/20 0.37
CCR1 P32246 1/20 0.36
RAB9A P51151 1/20 0.36
CCR5 P51681 1/20 0.36
MAPT P10636 2/20 0.35
CYP4F2 P78329 1/20 0.34
CYP4A11 Q02928 1/20 0.34
GFER P55789 1/20 0.33
EGFR P00533 2/20 0.33
ERBB2 P04626 1/20 0.33
MEN1 O00255 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
KMT2A Q03164 1/20 0.32
ADORA1 P30542 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21736916 0.82 S1PR4 (0.49) KDM4EALDH1A1S1PR4HPGDHSD17B10
SCHEMBL18149530 0.82 CRHBP (0.39) CCR1KMT2A
SCHEMBL17300098 0.78 KDM4E (0.61) KDM4EALDH1A1S1PR4HPGDHSD17B10
SCHEMBL29760903 0.76 KDM4E (0.42) KDM4EALDH1A1S1PR4HPGDHSD17B10
SCHEMBL1506555 0.76 S1PR4 (0.35) S1PR4
SCHEMBL8029116 0.76 KDM4E (0.42) KDM4EALDH1A1S1PR4HPGDHSD17B10
SCHEMBL18640593 0.74 KDM4E (0.41) KDM4EALDH1A1S1PR4HPGDHSD17B10
SCHEMBL12436364 0.72 KDM4E (0.42) KDM4EALDH1A1HPGDHSD17B10USP2
SCHEMBL20008568 0.71 KDM4E (0.38) KDM4EALDH1A1HPGDHSD17B10USP2
SCHEMBL3067223 0.71 KDM4E (0.42) KDM4EALDH1A1S1PR4HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10160748-B2 Indazolones as modulators of tnf signaling ABBVIE INC. (US) 2018-12-25 US disclosed
US-20180086737-A1 INDAZOLONES AS MODULATORS OF TNF SIGNALING ABBVIE INC. 2018-03-29 US disclosed
EP-3294726-A1 INDAZOLONES AS MODULATORS OF TNF SIGNALING AbbVie Inc. (US) 2018-03-21 EP disclosed
US-20160304496-A1 INDAZOLONES AS MODULATORS OF TNF SIGNALING ABBVIE INC. 2016-10-20 US disclosed
WO-2016168633-A1 INDAZOLONES AS MODULATORS OF TNF SIGNALING ABBVIE INC. (US) 2016-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160304496-A1 INDAZOLONES AS MODULATORS OF TNF SIGNALING TNF, CD40, TNFRSF1A KDM4E 4111/4885ALDH1A1 1402/4885S1PR4 1908/4885
US-20180086737-A1 INDAZOLONES AS MODULATORS OF TNF SIGNALING TNF, CD40, TNFRSF1A KDM4E 4111/4885ALDH1A1 1402/4885S1PR4 1908/4885
US-10160748-B2 Indazolones as modulators of tnf signaling TNF, CD40, TNFRSF1A KDM4E 4111/4885ALDH1A1 1402/4885S1PR4 1908/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.